CLEVELAND--(BUSINESS WIRE)--ImageIQ, an innovative Imaging Software and Contract Research Organization for preclinical research and clinical trials, announced today that it has been chosen by ContraVir Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery and development of targeted antiviral therapies, to provide its full complement of clinical research imaging support services and technology for ContraVir’s Phase III clinical trial of FV-100, an orally available nucleoside analogue prodrug for the treatment of shingles, an infection caused by the reactivation of varicella zoster virus (VZV), and shingles-associated pain, known as post-herpetic neuralgia (PHN). Specifically, ContraVir will leverage ImageIQ’s EDCIQ™ imaging-enabled electronic data capture (EDC) system, customized specifically to the study’s design and workflow to support the management and compliance of all imaging-related activities. ImageIQ will deploy, manage and support mobile imaging devices for field personnel who will capture images of the zoster rash for each study participant across multiple time points. Once acquired, images and data will be automatically uploaded to the EDCIQ by a mobile application for immediate centralized QA and reporting, followed by Dermatologist image evaluation using an EDCIQ integrated image viewer and measurements tools. Lastly, ImageIQ will develop and validate the imaging and image evaluation protocols, as well as provide image acquisition qualification, training, and imaging-related management for all study sites and field personnel participating in the study. ImageIQ is a Cleveland Clinic Innovations company.
Help employers find you! Check out all the jobs and post your resume.
